GLP-1 for PCOS

Polycystic ovary syndrome (PCOS) is a common hormonal disorder affecting an estimated 8–13% of women of reproductive age. It is characterised by androgen excess, ovulatory dysfunction, and often polycystic ovarian morphology on ultrasound. Symptoms can include irregular or absent menstrual periods, excess hair growth, acne, and difficulty conceiving.

Insulin resistance is a central feature of PCOS, present in the majority of affected women regardless of body weight. Excess weight amplifies insulin resistance and worsens both the metabolic and reproductive manifestations of PCOS, creating a cycle that is difficult to break with lifestyle change alone.

No GLP-1 receptor agonist is FDA-approved specifically for PCOS. Their use in this condition is off-label, typically considered when PCOS coexists with overweight or obesity and when first-line approaches — lifestyle modification and metformin — have not achieved adequate control. The evidence base has grown substantially since 2022, with multiple randomised trials and meta-analyses now available.

The most comprehensive recent evidence comes from a 2024 systematic review and meta-analysis published in Obesity Reviews, conducted to inform the international PCOS guideline. It found that anti-obesity pharmacological agents including GLP-1 receptor agonists produced significant reductions in BMI, waist circumference, and fasting insulin compared to placebo in women with PCOS. [1]

A 2024 meta-analysis of randomised controlled trials in women with PCOS and obesity confirmed that GLP-1 agonists significantly reduced body weight and improved hormonal regulation, including reductions in free androgen levels and improvements in menstrual regularity, with an acceptable safety profile. [2]

A 2024 systematic review and meta-analysis in Archives of Physiological Biochemistry, pooling data from multiple RCTs, found GLP-1 receptor agonists were effective and safe for PCOS, reducing BMI, fasting glucose, fasting insulin, and HOMA-IR (a marker of insulin resistance). [3]

In a phase 3 placebo-controlled RCT published in Fertility & Sterility, liraglutide 3 mg daily in women with obesity and PCOS produced significant reductions in body weight and meaningful improvements in metabolic parameters including fasting insulin, HOMA-IR, and total testosterone compared to placebo. [4]

Adding liraglutide to metformin (the traditional first-line agent for insulin resistance in PCOS) improved gonadal and metabolic profiles beyond metformin alone in overweight women with PCOS, suggesting additive benefit beyond what metformin achieves independently. [5]

Data from a 2-year observational study by Jensterle et al. showed that weight loss achieved with semaglutide in obese women with PCOS was largely maintained after semaglutide withdrawal in those continued on metformin, pointing to a durable metabolic reset in this population. [6]

A 2023 narrative review in the Journal of Clinical Medicine synthesised the mechanistic rationale: GLP-1 receptor agonists reduce hepatic glucose output, improve pancreatic beta-cell function, and lower hyperinsulinaemia — all drivers of androgen overproduction in PCOS. The authors concluded that GLP-1 analogs hold a meaningful, if off-label, role in PCOS management. [7]

A 2019 meta-analysis comparing GLP-1 receptor agonists directly to metformin in PCOS found comparable or superior effects on BMI and insulin resistance, with GLP-1 RAs showing greater weight reduction while metformin showed stronger glucose-lowering in some analyses. This head-to-head comparison supports individualising therapy based on the patient's primary burden. [8]

Women with PCOS and a BMI of 27 or above who have not achieved adequate metabolic or hormonal control with lifestyle modification alone or with metformin.

Women with PCOS and documented insulin resistance or prediabetes, where the insulin-sensitising and weight-loss effects of GLP-1 agonists may address both the metabolic and reproductive drivers of PCOS simultaneously.

Women with PCOS who are not pregnant, not planning pregnancy imminently, and using reliable contraception — GLP-1s must be stopped before conception.

Because GLP-1 use in PCOS is off-label, prescribers should document the clinical rationale, discuss the evidence honestly, and consider shared decision-making. Some payers require a prior authorisation citing the obesity or prediabetes comorbidity rather than PCOS itself.

No GLP-1 receptor agonist is FDA-approved for PCOS — this is off-label prescribing. Patients should understand they are using a drug approved for obesity or type 2 diabetes, applied to a related condition with growing but not definitive evidence.

Metformin remains the established first-line pharmacological agent for insulin resistance and metabolic dysfunction in PCOS and is far less expensive. GLP-1s are typically considered when metformin is inadequate or not tolerated, or when substantial weight loss is needed.

GLP-1 receptor agonists are contraindicated in pregnancy and should be stopped at least 2 months before a planned conception attempt. Because ovulation may resume with weight loss, reliable contraception is essential during therapy.

Evidence on fertility outcomes — IVF success rates, live birth rates — with GLP-1 use in PCOS is still limited. Improvements in menstrual regularity and ovulation frequency have been reported, but GLP-1s should not be presented as a fertility treatment.

Gastrointestinal side effects (nausea, vomiting, diarrhoea) are the most common adverse effects and are dose-dependent. Slow titration minimises these. Rare serious risks — pancreatitis, gallbladder disease — apply equally to women with PCOS.

Androgenic symptoms such as hirsutism and acne may improve modestly with weight loss and reduced hyperinsulinaemia, but GLP-1s should not be substituted for targeted treatments (anti-androgens, oral contraceptives) where those are indicated.